Sodium-glucose co-transporter 2 inhibitors (SGLT2-is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are newer DM medications that have shown CVD benefit [2]. This evidence concerns the gene GLP1R and diabetes mellitus.